SEC31 Antibody

What is SEC31 and why are antibodies against it important in research?

SEC31 is a component of the coat protein complex II (COPII), which plays a crucial role in the formation of transport vesicles from the endoplasmic reticulum (ER). In humans, there are two homologs: SEC31A and SEC31B. SEC31A is a 1,220 amino acid protein characterized by seven WD repeats that form a tertiary propeller configuration, while SEC31B (also known as SEC31L2) is a 1,179 amino acid protein with a mass of 128.7 kDa . These proteins are essential for both the physical deformation of the ER membrane into vesicles and the selection of cargo molecules during vesicular transport .

Antibodies against SEC31 proteins are important research tools because they enable scientists to study vesicular trafficking mechanisms, which are fundamental to understanding cellular transport processes, protein secretion pathways, and related disorders. These antibodies allow visualization and quantification of SEC31 proteins in various experimental contexts, contributing to our understanding of intracellular transport mechanisms.

What are the key differences between SEC31A and SEC31B antibodies?

SEC31A and SEC31B antibodies target distinct protein homologs with different expression patterns and potentially different functional roles:

While both antibodies target proteins involved in COPII-mediated transport, researchers should select the appropriate antibody based on the specific homolog being studied and the experimental requirements .

What are the common applications for SEC31 antibodies in research?

SEC31 antibodies are utilized across multiple experimental techniques in cell biology and biochemistry research:

• Western Blot (WB): The most widely used application for detecting SEC31 proteins in cell or tissue lysates. SEC31A typically appears as a band at approximately 133 kDa .

• Immunoprecipitation (IP): Used to isolate SEC31 and its interacting proteins from complex biological samples .

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Enables visualization of SEC31 localization within cells, typically showing cytoplasmic vesicular patterns associated with the ER and vesicular transport structures .

• Immunohistochemistry (IHC): Applied to tissue sections to study SEC31 expression patterns across different tissue types and disease states .

• Flow Cytometry (FCM): Particularly useful with SEC31B antibodies for quantitative analysis of protein expression levels .

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative detection of SEC31 proteins in solution .

The appropriate method should be selected based on research questions, sample types, and whether quantitative or qualitative data is required. For optimal results, researchers should verify that their chosen antibody has been validated for their specific application .

How should researchers validate SEC31 antibodies before experimental use?

Proper validation of SEC31 antibodies is crucial for experimental success and data reliability. A comprehensive validation strategy should include:

For advanced applications such as immunofluorescence or immunohistochemistry, additional validation steps should include comparing staining patterns with literature reports and confirming subcellular localization consistency with established SEC31 distribution (membrane, cytoplasmic vesicles, ER, and cytoplasm) . When performing co-localization studies, researchers should verify that the SEC31 antibody does not cross-react with other COPII components that might share structural similarities.

What are the optimal conditions for using SEC31 antibodies in Western blotting experiments?

Achieving optimal Western blot results with SEC31 antibodies requires careful consideration of several technical parameters:

• Sample preparation: Cell lysis buffers containing 1% NP-40 or RIPA buffer supplemented with protease inhibitors are generally effective for extracting SEC31 proteins. For SEC31A detection, HeLa cell lysates serve as positive controls, with optimal loading amounts ranging from 5-50 μg of total protein .

• SDS-PAGE conditions: Use 6-8% gels or gradient gels (4-12%) to properly resolve the high molecular weight SEC31 proteins (~128-133 kDa). Extended separation times may improve resolution.

• Transfer conditions: Wet transfer systems with methanol-free transfer buffer at lower currents (e.g., 30V overnight) often yield better results for large proteins like SEC31.

• Blocking and antibody incubation: 5% non-fat dry milk or BSA in TBST are suitable blocking agents. Primary antibody dilutions typically range from 1:500 to 1:2000, depending on the specific antibody. Incubation at 4°C overnight generally provides optimal results .

• Detection optimization: For SEC31A antibodies such as ab86600, exposure times as short as 3 seconds can produce clear signals when using chemiluminescent detection systems .

When troubleshooting weak or non-specific signals, researchers should consider adjusting antibody concentration, extending incubation times, or exploring alternative detection methods. For quantitative analyses, researchers should verify the linear range of detection for their specific SEC31 antibody.

How can researchers effectively use SEC31 antibodies to study COPII vesicle formation dynamics?

Studying COPII vesicle formation dynamics with SEC31 antibodies requires sophisticated approaches that capture both spatial and temporal aspects of this process:

• Live-cell imaging: For real-time visualization of COPII dynamics, researchers can use fluorescently-tagged SEC31 antibody fragments (Fab) that can enter cells without disrupting normal function. Alternatively, cell lines stably expressing fluorescently-tagged SEC31 can be generated.

• Super-resolution microscopy: Techniques such as STORM, PALM, or structured illumination microscopy combined with SEC31 antibodies can reveal the nanoscale organization of COPII vesicles and the precise arrangement of SEC31 within coat structures.

• Pulse-chase experiments: By synchronizing COPII vesicle formation (using temperature blocks or small molecule inhibitors) followed by fixation at different time points and SEC31 antibody staining, researchers can capture sequential stages of vesicle formation.

• Co-localization studies: Dual immunofluorescence with antibodies against SEC31 and other COPII components (SEC23/24, SAR1) or cargo proteins can provide insights into assembly kinetics and cargo selection mechanisms.

• Correlative light and electron microscopy (CLEM): This approach combines the specificity of SEC31 antibody labeling with the ultrastructural resolution of electron microscopy to visualize the morphology of COPII vesicles and coat components.

For quantitative analysis of SEC31 dynamics, fluorescence recovery after photobleaching (FRAP) or fluorescence loss in photobleaching (FLIP) can be combined with SEC31 antibodies or fluorescently-tagged SEC31 to measure protein turnover rates at ER exit sites. These approaches have revealed that SEC31 has a more dynamic association with membranes compared to other COPII components, suggesting regulatory roles in coat assembly and disassembly.

How should researchers address potential cross-reactivity between SEC31A and SEC31B antibodies?

Cross-reactivity between SEC31A and SEC31B antibodies represents a significant challenge due to the structural similarities between these homologs. Researchers can implement several strategies to address this issue:

• Epitope analysis: Select antibodies raised against regions with minimal sequence homology between SEC31A and SEC31B. The middle region antibodies for SEC31B and antibodies targeting specific regions of SEC31A (aa 750-850 or aa 600-800) may offer better specificity .

• Validation in knockout/knockdown systems: Confirm antibody specificity by testing in cell lines where either SEC31A or SEC31B has been specifically depleted through CRISPR/Cas9 knockout or RNAi knockdown.

• Differential expression analysis: Leverage the distinct expression patterns of these proteins—SEC31A is widely expressed, while SEC31B shows specific expression in thymus and testis . Testing antibodies in tissues with known differential expression can confirm specificity.

• Immunoprecipitation followed by mass spectrometry: This approach can unambiguously identify which SEC31 isoform is being detected by a given antibody.

• Dual detection experiments: Use proven isoform-specific antibodies alongside the antibody being tested to compare detection patterns and confirm specificity.

When reporting research findings, researchers should explicitly state which SEC31 isoform was targeted and provide evidence of antibody specificity to ensure reproducibility and accurate interpretation of results.

What are the key considerations when using SEC31 antibodies for immunofluorescence studies?

Successful immunofluorescence studies with SEC31 antibodies require attention to several critical parameters:

When analyzing immunofluorescence data, quantitative approaches such as Manders' or Pearson's correlation coefficients can provide objective measures of co-localization between SEC31 and other proteins of interest. For publications, representative images should include scale bars and clear descriptions of the imaging parameters used.

How can researchers optimize immunoprecipitation protocols for studying SEC31 protein interactions?

Optimizing immunoprecipitation (IP) protocols for SEC31 protein interactions requires careful consideration of buffer composition, antibody selection, and experimental controls:

• Lysis buffer optimization: For COPII components like SEC31, gentle lysis buffers containing 0.5-1% NP-40 or Triton X-100 with physiological salt concentrations (150mM NaCl) help preserve protein-protein interactions. For capturing transient interactions, crosslinking with formaldehyde (0.1-0.5%) prior to lysis may be beneficial.

• Antibody selection and coupling: Choose SEC31 antibodies validated for IP applications, such as those designated with "IP" functionality in product descriptions . For cleaner results, consider coupling the antibody to protein A/G beads or using pre-coupled commercial preparations.

• Incubation conditions: For detecting stable SEC31 interactions, incubate lysates with antibody-coupled beads for 2-4 hours at 4°C. For capturing weaker or transient interactions, extend incubation times (overnight) and optimize salt and detergent concentrations.

• Washing stringency: Balance between preserving specific interactions and reducing background. Typically, 3-5 washes with lysis buffer or decreasing detergent concentrations are effective for SEC31 IPs.

• Elution methods: For mass spectrometry applications, consider native elution with competing peptides or low-pH glycine buffers rather than boiling in SDS to reduce antibody contamination.

• Controls: Always include:

  • Isotype control antibodies to identify non-specific binding

  • Input samples (5-10% of material used for IP)

  • Reciprocal IPs when studying specific interactions (e.g., IP with anti-SEC23 to confirm SEC31 interaction)

For detecting SEC31 phosphorylation or ubiquitination, include phosphatase inhibitors (sodium fluoride, sodium orthovanadate) or deubiquitinase inhibitors (N-ethylmaleimide) in lysis buffers. When analyzing SEC31 interactions by mass spectrometry, researchers should be aware that other COPII components (SEC13, SEC23/24) are likely to co-precipitate due to their association in the coat complex .

How are SEC31 antibodies utilized in studying disease models related to ER-Golgi trafficking defects?

SEC31 antibodies have become instrumental in investigating disease models where ER-Golgi trafficking abnormalities contribute to pathogenesis:

• Neurodegenerative disorders: In models of Alzheimer's, Parkinson's, and Huntington's diseases, SEC31 antibodies help researchers visualize alterations in COPII-mediated transport that may contribute to protein aggregation and ER stress. Dual labeling with SEC31 and disease-associated proteins (e.g., α-synuclein, huntingtin) can reveal spatial relationships between transport defects and protein aggregation.

• Cancer research: Chromosomal aberrations involving SEC31A have been linked to inflammatory myofibroblastic tumors, indicating potential involvement in carcinogenesis . Researchers use SEC31 antibodies to assess COPII component expression and localization in tumor samples compared to normal tissues.

• Metabolic disorders: In models of diabetes and obesity, SEC31 antibodies help visualize alterations in the trafficking of insulin receptors, glucose transporters, and lipid metabolism enzymes from the ER to the cell surface.

• Hereditary protein trafficking disorders: Conditions such as cranio-lenticulo-sutural dysplasia (CLSD, caused by SEC23A mutations) can be studied using SEC31 antibodies to assess how primary defects in one COPII component affect the localization and function of others.

• Viral infection models: SEC31 antibodies are used to investigate how viruses manipulate the host secretory pathway. For example, some viruses may cause relocalization of SEC31 to viral replication compartments.

For these studies, researchers typically combine immunofluorescence or immunohistochemistry with SEC31 antibodies and quantitative image analysis to measure parameters such as the number, size, and distribution of SEC31-positive structures. These measurements provide objective metrics for comparing normal and disease states or assessing the effects of therapeutic interventions targeting ER-Golgi trafficking.

What approaches can be used to study SEC31 post-translational modifications and their functional impacts?

SEC31 proteins undergo various post-translational modifications (PTMs) that regulate their function in COPII vesicle formation. Studying these modifications requires specialized approaches:

• Phosphorylation analysis:

  • Western blotting with phospho-specific SEC31 antibodies (when available) or general phospho-serine/threonine antibodies after SEC31 immunoprecipitation

  • Phos-tag SDS-PAGE followed by SEC31 immunoblotting to separate phosphorylated from non-phosphorylated forms

  • Mass spectrometry analysis of immunoprecipitated SEC31 to identify specific phosphorylation sites

• Ubiquitination studies:

  • SEC31B is known to undergo ubiquitination as a post-translational modification

  • Immunoprecipitate SEC31 under denaturing conditions followed by ubiquitin immunoblotting

  • Use tagged ubiquitin constructs (His-Ub or HA-Ub) and corresponding antibodies for pull-down experiments

  • Mass spectrometry to identify ubiquitination sites and types (K48 vs. K63 linkages)

• Functional impact assessments:

  • Site-directed mutagenesis of identified PTM sites followed by functional rescue experiments

  • Pharmacological inhibition of specific kinases or the ubiquitin-proteasome system

  • Correlation of PTM status with COPII vesicle size or cargo selection using quantitative microscopy

  • In vitro reconstitution assays with purified components to test how PTMs affect SEC31 assembly properties

• Temporal dynamics:

  • Synchronize ER exit using temperature-sensitive cargo and monitor SEC31 PTM changes over time

  • Use phosphatase or deubiquitinase inhibitors to trap modified forms for analysis

When designing these experiments, researchers should consider that PTMs likely regulate SEC31 function by altering its interactions with other COPII components or affecting its membrane association properties. Therefore, combining PTM analysis with interaction studies provides deeper mechanistic insights into SEC31 regulation.

How can researchers effectively combine SEC31 antibodies with advanced imaging techniques?

Integrating SEC31 antibodies with cutting-edge imaging approaches enables deeper insights into COPII vesicle dynamics and structure:

• Super-resolution microscopy:

  • STORM/PALM: Use photoswitchable fluorophore-conjugated secondary antibodies with SEC31 primaries to achieve 20-30nm resolution of COPII structures

  • SIM (Structured Illumination Microscopy): Requires less specialized probes while still providing ~100nm resolution to visualize SEC31 arrangement within COPII coats

  • Sample preparation considerations: Standard immunofluorescence protocols should be optimized for signal-to-noise ratio and use high-quality primary SEC31 antibodies

• Live-cell imaging strategies:

  • SEC31-specific nanobodies or Fab fragments conjugated to cell-permeable fluorophores

  • Correlation of fixed-cell SEC31 antibody staining with live-cell phase contrast or fluorescent cargo markers

  • FRAP (Fluorescence Recovery After Photobleaching) analysis with fluorescently-tagged SEC31 to measure dynamics at specific cellular locations

• Correlative Light and Electron Microscopy (CLEM):

  • Use SEC31 antibodies for immunofluorescence followed by sample processing for electron microscopy

  • Gold-conjugated secondary antibodies can be used for immunoelectron microscopy to visualize SEC31 at ultrastructural resolution

  • Enables correlation between fluorescence patterns and membrane morphology at ER exit sites

• Single-molecule approaches:

  • Single-molecule tracking of SEC31 using quantum dot-conjugated antibodies

  • Single-molecule pull-down assays to detect specific protein-protein interactions

  • Requires careful antibody fragmentation or small epitope tags to minimize steric hindrance

• Expansion microscopy:

  • Physical expansion of fixed specimens labeled with SEC31 antibodies can provide super-resolution-like images on standard confocal microscopes

  • Requires optimization of fixation and labeling protocols to maintain epitope accessibility after expansion

For quantitative analysis, researchers should employ automated image analysis workflows to measure parameters such as SEC31 puncta density, size distribution, signal intensity, and co-localization with other markers. These approaches can reveal subtle phenotypes in genetic perturbation studies that might be missed by qualitative assessment.

What are the most common issues encountered when using SEC31 antibodies and how can they be resolved?

Researchers working with SEC31 antibodies may encounter several technical challenges. Here are the most common issues and their solutions:

For SEC31A detection by Western blot, researchers should note that published data shows consistent detection at approximately 133 kDa, matching the predicted size . When troubleshooting SEC31B antibodies, remember that expression levels are generally low except in thymus and testis tissues, which may be used as positive controls .

If cross-reactivity between SEC31A and SEC31B is suspected, perform control experiments with samples known to express only one isoform or use knockout/knockdown approaches to confirm specificity.

How should researchers interpret unexpected results when using SEC31 antibodies?

When unexpected results emerge with SEC31 antibodies, systematic analysis can help determine whether the observations represent genuine biological phenomena or technical artifacts:

• Unexpected subcellular localization:

  • Verify with multiple antibodies targeting different SEC31 epitopes

  • Consider cell type-specific differences in SEC31 distribution

  • Examine cell health and stress status, as ER stress can alter COPII organization

  • Compare with published localization patterns for SEC31 in similar cell types

• Unexpected molecular weight:

  • For SEC31A, the expected molecular weight is approximately 133 kDa

  • For SEC31B, the expected molecular weight is approximately 128.7 kDa

  • Higher molecular weight bands may represent post-translationally modified forms

  • Lower molecular weight bands may represent isoforms (up to 5 different isoforms have been reported for SEC31B) or degradation products

• Unexpected expression levels:

  • SEC31B is generally expressed at low levels except in thymus and testis

  • SEC31A is more widely expressed and may show variable levels depending on cellular demand for secretion

  • Verify RNA expression data (e.g., from public databases) to corroborate protein findings

  • Consider whether experimental manipulations might alter SEC31 expression

• Conflicting co-localization results:

  • SEC31 associates dynamically with other COPII components

  • Fixation method can affect preservation of transient interactions

  • Consider using proximity ligation assays (PLA) to verify protein-protein interactions in situ

  • Compare results across multiple microscopy platforms and preparation methods

How might emerging technologies enhance the utility of SEC31 antibodies in research?

Emerging technologies are poised to revolutionize how researchers use SEC31 antibodies, offering new insights into COPII vesicle biology:

• Next-generation antibody formats:

  • Single-domain antibodies (nanobodies) against SEC31 could enable super-resolution microscopy with minimal linkage error

  • Bispecific antibodies targeting SEC31 and cargo proteins could reveal spatial relationships during trafficking

  • Intrabodies expressed in specific cellular compartments could enable targeted manipulation of SEC31 function

• Advanced proteomics approaches:

  • Proximity labeling methods (BioID, APEX) combined with SEC31 antibodies for immunoprecipitation could identify novel interaction partners

  • Cross-linking mass spectrometry (XL-MS) after SEC31 immunoprecipitation could map structural relationships within the COPII coat

  • Targeted proteomics using SEC31 antibodies for immunoprecipitation followed by selected reaction monitoring (SRM) could enable precise quantification of SEC31 PTMs

• Spatial transcriptomics and proteomics:

  • Combining SEC31 immunofluorescence with in situ RNA sequencing could reveal spatial relationships between SEC31-positive structures and local translation

  • Multiplex ion beam imaging (MIBI) or imaging mass cytometry with SEC31 antibodies could enable simultaneous detection of dozens of proteins at subcellular resolution

• Cryo-electron tomography:

  • Correlative approaches using SEC31 antibodies for light microscopy followed by cryo-ET could reveal the native architecture of COPII coats in cellular contexts

  • Immunogold labeling with SEC31 antibodies could precisely localize SEC31 within reconstructed COPII vesicle coats

• Artificial intelligence applications:

  • Machine learning algorithms trained on SEC31 immunofluorescence patterns could automatically identify and classify COPII structures

  • Deep learning approaches could predict SEC31 behavior based on multi-parametric imaging data

These technologies will enable researchers to move beyond descriptive studies of SEC31 localization toward functional understanding of how SEC31 dynamics contribute to COPII vesicle formation, cargo selection, and trafficking in both normal and disease states.

What are the key unresolved questions about SEC31 that antibody-based research might address?

Despite significant advances in understanding SEC31 biology, several important questions remain that could be addressed through innovative applications of SEC31 antibodies:

• Structural dynamics of SEC31 in COPII assembly:

  • How does the conformation of SEC31 change during coat assembly and disassembly?

  • What are the molecular mechanisms by which SEC31 contributes to membrane curvature?

  • How do SEC31A and SEC31B differ in their structural roles within the COPII coat?

  These questions could be addressed using conformation-specific SEC31 antibodies combined with super-resolution microscopy or single-molecule approaches.

• Regulation of SEC31 function:

  • How do post-translational modifications like ubiquitination specifically alter SEC31B function ?

  • What is the precise temporal sequence of SEC31 recruitment and modification during COPII vesicle formation?

  • How do cellular stress conditions modulate SEC31 function and localization?

  Researchers could develop modification-specific antibodies or combine existing SEC31 antibodies with cellular perturbations and quantitative imaging to address these questions.

• Isoform-specific functions:

  • What are the functional differences between SEC31A and SEC31B?

  • Do the five reported isoforms of SEC31B have distinct roles in particular tissues or developmental stages?

  • How do SEC31 homologs interact differently with other COPII components?

  Isoform-specific SEC31 antibodies used in comparative studies across tissues and developmental stages could provide insights into these questions.

• Role in disease processes:

  • How do alterations in SEC31 function contribute to specific disease phenotypes?

  • Could SEC31 serve as a diagnostic marker for disorders involving secretory pathway dysfunction?

  • Are there disease-specific SEC31 variants or modifications that could be targeted therapeutically?

  Patient-derived samples analyzed with SEC31 antibodies, combined with functional studies in disease models, could help address these clinically relevant questions.

By combining sophisticated antibody-based approaches with complementary technologies, researchers can continue to advance our understanding of SEC31 biology and its implications for cellular function in health and disease.